DexCom (NASDAQ:DXCM) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of DexCom (NASDAQ:DXCM) from a hold rating to a buy rating in a research note released on Tuesday morning.

A number of other research analysts also recently commented on the stock. Baird R W downgraded shares of DexCom from a strong-buy rating to a hold rating in a research note on Friday, July 26th. Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a buy rating in a report on Friday, August 23rd. Piper Sandler restated an overweight rating and set a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Morgan Stanley reduced their target price on DexCom from $120.00 to $75.00 and set an equal weight rating on the stock in a report on Friday, July 26th. Finally, Robert W. Baird upped their price target on DexCom from $80.00 to $82.00 and gave the stock a neutral rating in a research note on Monday, August 5th. Six investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $112.25.

DexCom Stock Up 1.2 %

Shares of NASDAQ DXCM opened at $67.53 on Tuesday. The firm has a market cap of $26.86 billion, a P/E ratio of 43.57, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The firm’s 50 day moving average price is $75.42 and its 200 day moving average price is $108.17.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.34 earnings per share. As a group, sell-side analysts anticipate that DexCom will post 1.69 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,824 shares of company stock valued at $126,390. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom in the 2nd quarter worth approximately $25,000. Sachetta LLC raised its position in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Crewe Advisors LLC purchased a new stake in shares of DexCom during the first quarter valued at $29,000. Riverview Trust Co purchased a new stake in shares of DexCom during the first quarter valued at $32,000. Finally, DT Investment Partners LLC boosted its position in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.